Amylin wins TRO against longtime partner Lilly; Neurosearch, 4SC scout for partners; Your brain on video games;

@FierceBiotech: Pfizer investigator questions cause of deaths in tofacitinib trial. News | Follow @FierceBiotech

@JohnCFierce: The $1B federal Therapeutic Discovery Program was a big hit with thousands of biotechs--now there's a new bill to add $7B more through 2017. | Follow @JohnCFierce

> Amylin has won the first round in its explosive case against Eli Lilly--a longtime development partner--as a U.S. District Judge issues a temporary restraining order against Lilly's co-marketing deal with rival Boehringer Ingelheim. Story

> Now that it's received U.S. and European regulatory feedback from Neurosearch for its obesity drug candidate, the Danish company says it is looking for a partner to take it forward. The feedback has given the biotech some key insights into the design of its clinical program for the drug. Article

> Bloomberg reports that 4SC is hoping that upcoming mid-stage data will set the stage for a partnership deal for its rheumatoid arthritis program. Item

> BioCis Pharma Oy and Oy Lx Therapies have combined to create Laurantis Pharma, a clinical-stage specialty pharmaceutical development company. The company's lead products target the treatment of a variety of inflammatory diseases and conditions including atopic dermatitis, dry eye syndrome, interstitial cystitis, and lymphatic disorders, as well as the treatment of bladder cancer. Release

> Arena Pharmaceuticals presented meta-analyses of the three trials in the lorcaserin Phase III clinical trial program at ECO 2011, the 18th European Congress on Obesity. Arena release

Pharma News

@FiercePharma: Vertex to field small, specialized sales force on Incivek. Item | Follow @FiercePharma

> Novartis aims for gout indication for Ilaris. Article

> NICE hurries to assess new hepatitis C drugs. Item

> Watson expands in Europe with $562M Specifar buy. News

> Nuedexta next in line for congressional questions. Story

> Bayer bias suit grows with new plaintiffs. Report

Vaccines News

> A look at HIV/AIDS vaccines in development. Story

> Prima BioMed to raise cash for ovarian cancer vaccine trial. News

> Systems biology key to vaccine breakthroughs? Report

> WHO: Smallpox vials around until at least 2014. Article

> Profectus immunizes first patient in Ph1 HIV vax trial. Item

Manufacturing News

> Cargo theft report puts pharma in 10th place. Story

> Pharma among NJ networks to seek info on employer skill needs. Item

> More wastewater treatment to keep drugs out of food. Report

> CMO Gallus taps Xcellerex for single-use capacity. Article

> Skills upgrade pulls manufacturing westward. Story

> CMOs boost R&D companies to top of efficiency ratings. News

And Finally... A new University of Missouri study suggests that the brains of violent video game players become less responsive to violence, and this diminished brain response predicts an increase in aggression. Release

Suggested Articles

LianBio aims to bring much-needed new drugs to China and serve as a partner for U.S. biotechs looking to expand into Asia.

Despite the setback, Fulcrum hailed the data as “very encouraging,” zeroing in on results from a pre-specified sensitivity analysis to make its case.

Bayer has struck a $425 million upfront deal to buy KaNDy in the belief its treatment for menopause-related hot flashes has blockbuster potential.